CD4 CAR+ ZFN-modified T Cells in HIV Therapy

Inclusion Criteria: * HIV-1 infection * Clinically stable on first or second HAART regimen * Screening CD4+ T cell count of ≥450 cells/mm3 within 30 days of enrollment; and a documented CD4 nadir of not lower than 200 cells/mm3 * Screening HIV-1 RNA that is ≤50 copies/mL within 30 days prior to enrollment * HIV-1 RNA ≤50 copies/mL for at least 24 weeks prior to enrollment * Adequate venous access and no other contraindications for leukapheresis * Laboratory values within certain parameters, obtained within 30 days prior to enrollment * Willing to comply with study-mandated evaluations * Male or female, 18 years of age or older * Ability and willingness to provide informed consent * Karnofsky Performance Score of 70 or higher * Negative HBsAg (hepatitis B) within 6 months prior to enrollment * Negative HCV (hepatitis C) serology, or if positive, negative HCV RNA within 6 months prior to enrollment * Have a recorded viral load set point prior to starting antiretroviral therapy Exclusion Criteria: * Acute or chronic hepatitis B or hepatitis C infection * Current or prior AIDS diagnosis * History of cancer or malignancy, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin * History or any features on physical examination indicative of active or unstable cardiac disease or hemodynamic instability (subjects with a history of cardiac disease may participate with a physician's approval) * History or any features of physical examination indi…